Abbott Laboratories (ABT)vsCME Group Inc (CME)
ABT
Abbott Laboratories
$84.32
-3.09%
HEALTHCARE · Cap: $151.56B
CME
CME Group Inc
$281.25
-1.95%
FINANCIAL SERVICES · Cap: $101.91B
Smart Verdict
WallStSmart Research — data-driven comparison
Abbott Laboratories generates 569% more annual revenue ($45.13B vs $6.74B). CME leads profitability with a 63.3% profit margin vs 13.9%. ABT appears more attractively valued with a PEG of 1.29. CME earns a higher WallStSmart Score of 65/100 (C+).
ABT
Buy56
out of 100
Grade: C
CME
Buy65
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+0.6%
Fair Value
$87.53
Current Price
$84.32
$3.21 discount
Intrinsic value data unavailable for CME.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Reasonable price relative to book value
Keeps 63 of every $100 in revenue as profit
Strong operational efficiency at 69.8%
Large-cap with strong market position
Conservative balance sheet, low leverage
Earnings expanding 21.3% YoY
Generating 1.2B in free cash flow
Areas to Watch
Weak financial health signals
Earnings declined 19.7%
Weak financial health signals
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : ABT
The strongest argument for ABT centers on Market Cap, Price/Book. PEG of 1.29 suggests the stock is reasonably priced for its growth.
Bull Case : CME
The strongest argument for CME centers on Profit Margin, Operating Margin, Market Cap. Profitability is solid with margins at 63.3% and operating margin at 69.8%. Revenue growth of 14.4% demonstrates continued momentum.
Bear Case : ABT
The primary concerns for ABT are Piotroski F-Score, EPS Growth.
Bear Case : CME
The primary concerns for CME are Piotroski F-Score, PEG Ratio.
Key Dynamics to Monitor
ABT profiles as a value stock while CME is a mature play — different risk/reward profiles.
ABT carries more volatility with a beta of 0.65 — expect wider price swings.
CME is growing revenue faster at 14.4% — sustainability is the question.
CME generates stronger free cash flow (1.2B), providing more financial flexibility.
Bottom Line
CME scores higher overall (65/100 vs 56/100), backed by strong 63.3% margins and 14.4% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Abbott Laboratories
HEALTHCARE · MEDICAL DEVICES · USA
Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.
Visit Website →CME Group Inc
FINANCIAL SERVICES · FINANCIAL DATA & STOCK EXCHANGES · USA
CME Group Inc. (Chicago Mercantile Exchange, Chicago Board of Trade, New York Mercantile Exchange, The Commodity Exchange) is an American global markets company. It is the world's largest financial derivatives exchange, and trades in asset classes that include agricultural products, currencies, energy, interest rates, metals, stock indexes and cryptocurrencies futures.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?